RASON promotes KRASG12C-driven tumor progression and immune evasion in non-small cell lung cancer

Abstract Background KRAS is the most frequently mutated oncogene in human cancers, with KRASG12C being a prevalent driver mutation in 12–13% non-small cell lung cancer (NSCLC) cases. Despite breakthroughs in KRASG12C inhibitors such as sotorasib (AMG-510) and adagrasib (MRTX-849), clinical resistanc...

Ausführliche Beschreibung

Bibliografische Detailangaben

Hauptverfasser:	Jianzhuang Wu, Kexin Xie, Yixuan Zhang, Weiyi Zhang, Rongjie Cheng, Yaliang Zhang, Yugui Xia, Tongyan Liu, Rong Yin, Yudong Qiu, Tao Xu, Rutian Li, Qi Sun, Chao Yan
Format:	Artigo
Sprache:	Inglês
Veröffentlicht:	BMC 2025-03-01
Schriftenreihe:	Journal of Experimental & Clinical Cancer Research
Schlagworte:	RASON KRAS Non-small cell lung cancer Immune evasion CD47
Online-Zugang:	https://doi.org/10.1186/s13046-025-03369-9
Tags:	Tag hinzufügen Keine Tags, Fügen Sie das erste Tag hinzu!